The cytogenetic evolution patterns in chronic myeloid leukemia (CML) after allogeneic (allo) stem cell transplantation (SCT) are different from the ones observed in non-transplanted patients, a phenomenon suggested to be caused by the conditioning regime. We reviewed 131 CMLs displaying karyotypic evolution after SCT (122 allo, nine autologous (auto)), treated at Lund University Hospital or reported in the literature. Major route abnormalities (i.e., þ 8, þ Ph, i(17q), þ 19, þ 21, þ 17 and À7) were seen in 14%, balanced aberrations in 61%, hyperdiploidy in 19%, pseudodiploidy in 79%, divergent clones in 14%, and Ph-negative clones in 21%. The breakpoints involved in secondary structural rearrangements clustered at 1q21, 1q32, 7q22, 9q34, 11q13, 11q23, 12q24, 13q14, 17q10 and 22q11. Cytogenetic abnormalities common in AML after genotoxic exposure, that is, der(1;7)(q10;p10), del(3p), À5, del(5q), À7, À17, der(17p), À18, and À21, were only rarely seen post-SCT. Comparing the cytogenetic features in relation to type of SCT revealed that balanced aberrations were significantly more common after allo than after auto SCT (64 and 22%, respectively, P ¼ 0.03). In addition, there was a trend as regards hyperdiploidy being more common after auto (P ¼ 0.07) and pseudodiploidy being more frequent after allo SCT (P ¼ 0.09). Possible reasons for these differences are discussed.
Introduction
Chronic myeloid leukemia (CML) is genetically characterized by the t(9;22)(q34;q11) that results in the Ph chromosome and a BCR/ABL1 fusion. 1 In the chronic phase (CP), the t(9;22), or a variant thereof, is most often the only cytogenetic aberration, whereas 60-80% of the cases acquire additional abnormalities during the accelerated phase and the blast crisis. 2 These secondary changes are clearly nonrandom, with the most common (34% to 5% of CMLs with secondary abnormalities) being þ 8, þ Ph, i(17q), þ 19, ÀY, þ 21, þ 17 and À7, referred to as 'major route abnormalities'. Less frequent aberrations, denoted 'minor route abnormalities', include trisomies of chromosomes 6, 10, 12, 14, and 17, monosomies 17 and 18, and deletions of 17p. Thus, with a few exceptions, such as t(3;21)(q26;q22) and inv(3)(q21q26), the additional changes are genomically unbalanced, resulting in gain or loss of genetic material. 2 Next to nothing is known about the mechanisms underlying the cytogenetic evolution during the disease progression of CML. However, the type of therapy given during the CP seems to play an important role. 2 For example, þ 8 is significantly more common after busulphan treatment as compared to CMLs treated with hydroxyurea, 2, 3 and it has been suggested that prior therapy with interferon-a (IFNa) is associated with higher frequencies of unusual secondary changes, that is, non-major route abnormalities, and 'divergent clones', that is, cell populations with unrelated aberrations in addition to the t(9;22). 2, 4, 5 Furthermore, emergence of Ph chromosomenegative cells with clonal chromosomal changes, mainly trisomy 8, [6] [7] [8] [9] has been reported after treatment with IFNa. Recently, several studies have shown that therapy with imatinib also is associated with such Ph chromosomenegative clones, again particularly with þ 8.
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The cytogenetic evolution patterns seen after allogeneic (allo)-SCT are generally different from the ones observed after treatment with busulphan, hydroxyurea, or IFNa, being seemingly random, rarely major route abnormalities, structurally complex, sometimes transient, with a high frequency of balanced translocations and divergent clones. 2, [18] [19] [20] [21] [22] [23] It has been suggested that these unusual abnormalities are caused by the conditioning regime, that is, occur as a consequence of the clastogenic effect of TBI and/or alkylating agents, most commonly CY. [21] [22] [23] [24] [25] [26] Although this may well be true, one could also postulate that the emergence of 'unconventional' cytogenetic evolution is facilitated -or even caused -by the altered BM environment, that is, the presence of donor cells and/or the immunosuppression post-allo-SCT. If so, one would suspect that the karyotypic patterns would be different after allo-and autologous (auto)-SCT, which have similar conditioning regimes. To characterize secondary chromo-somal changes post-SCT and to compare the cytogenetic evolution patterns post-allo-and auto-SCT, we ascertained and cytogenetically reviewed all CML patients having undergone SCT in our hospital as well as all published 27 CMLs displaying cytogenetic evolution after allo-and auto-SCT.
Patients and methods

Patients
The patient cohort is comprised of a consecutive series of 56 patients (16 women, 40 men, median age at the time of SCT 37.5 years, range 4-55 years) with Ph chromosomepositive CML undergoing SCT at the Department of Hematology, Lund University Hospital, Sweden, between 1986 and 2004. Secondary chromosomal aberrations or cytogenetically abnormal, but Ph chromosome-negative, clones were found in 13 of the 49 patients treated with allo-SCT and in three of the seven patients receiving auto-SCT. The conditioning regime included fTBI and/or an alkylating agent in all cases. The cytogenetic and clinical features of the 16 patients are given in Table 1 .
Cytogenetic and fluorescence in situ hybridization analyses BM preparations and G-banding analyses were performed according to standard methods, and the clonality criteria and description of karyotypes followed the recommendations of ISCN (2005). 28 As Chase et al. 26 reported a high frequency of 13q abnormalities, most often involving 13q12-14, in CMLs after allo-SCT we also specifically looked for such changes using fluorescence in situ hybridization (FISH) in nine cases where sufficient material was available for analysis. The following probes were used: LSI 13 for RB1 at 13q14 (Abbott, Stockholm, Sweden), BCR/ABL1 dual color, dual fusion (Abbott, Stockholm, Sweden), and RP11-310D8 (BACPAC Resources, Children's Hospital Oakland Research Institute, Oakland, CA, USA) mapping to distal 13q.
Cases from the literature The Mitelman Database of Chromosome Aberrations in Cancer 27 was used to ascertain previously published Ph chromosome-positive CMLs (N ¼ 2910). Then, all cases displaying either secondary changes in addition to t (9;22) or cytogenetically abnormal, but Ph chromosome-negative, clones after SCT were identified. Of the 115 cases found, 109 had undergone allo 2, 12, [18] [19] [20] [22] [23] [24] [25] [26] and six auto-SCT. 7, 12, 50, [52] [53] [54] The conditioning regime included TBI and/ or an alkylating agent in all (100%) of the 101 cases for which such data were available. Of the 109 allo-SCT cases (67 males, 42 females), 62 were transplanted in chronic phase and 18 in accelerated phase or blast crisis; the disease phase was not reported for the remaining 29 cases. For the six auto-SCT cases (three males, three females), the respective numbers were 3, 1 and 2. Information regarding age at transplantation, pre-transplant treatment, and time to SCT was rarely reported; the impact of these variables could hence not be analyzed in the present study.
Cytogenetic patterns ascertained
The presence of the following abnormalities/aberration patterns were investigated in a total of nine CMLs after auto-SCT and 122 after allo-SCT (cases from Lund and the literature combined): major route abnormalities ( þ 8, þ Ph, i(17q), þ 19, þ 21, þ 17, À7) in Ph-positive clones, balanced aberrations as such (in addition to the 9;22-translocation), modal chromosome numbers (o45, 46 and 447 chromosomes), divergent clones (cell populations with unrelated aberrations in addition to the 9;22-translocation), and Ph-negative clones. Furthermore, all chromosome breakpoints were ascertained in each karyotype in order to identify frequently rearranged chromosome bands postallo-and auto-SCT.
As mentioned above, the conditioning regime included TBI and/or an alkylating agent in all CML cases in which such information was available. As these therapeutic modalities are known to be associated with treatmentrelated AML (t-AML) with characteristic chromosomal abnormalities, we also ascertained the frequencies of der(1;7)(q10;p10), del(3p), À5, del(5q), À7, À17, der(17p), À18, and À21, all of which have been shown to be significantly (Po0.001) more common in t-AML arising after previous exposure to irradiation and/or alkylating agents. 55 
Statistical analyses
Fisher's exact test was used to analyze differences in secondary aberration patterns between allo-and auto-SCT and to compare the frequencies of der(1;7)(q10;p10), del(3p), À5, del(5q), À7, À17, der(17p), À18, and À21 in t-AML and CML cases post-SCT. Po0.05 were considered statistically significant.
Results
Secondary abnormalities/abnormality patterns after auto-and allo-SCT Of the nine auto-SCT cases, two (22%) displayed major route abnormalities, both including þ 8. Sixteen (13%) of the 122 CMLs treated with allo-SCT harbored one or several major route abnormalities, the most common being þ 8 and þ Ph. Overall, there was no significant frequency difference (P40.30) of major route abnormalities or divergent clones between the two groups. The frequencies of the various modal numbers did not differ significantly, although there was a trend towards significance as regards pseudodiploidy (P ¼ 0.09) being more frequent after allo and hyperdiploidy (P ¼ 0.07) being more common after auto-SCT. Ph-negative clones were more common after auto-SCT (P ¼ 0.003), whereas balanced aberrations, mainly translocations, were more frequent after allo-SCT (P ¼ 0.03) ( Table 2) .
Aberrations characteristic for t-AML in CML cases post-SCT None of the abnormalities der(1;7)(q10;p10), del(3p), À5, del(5q), À7, À17, der(17p), À18, and À21 were particularly common after SCT as compared to t-AML; in fact, many of them were significantly more frequent in t-AML (Table 3) .
Breakpoint map of secondary rearrangements occurring after SCT in Ph-positive CML The breakpoints involved in secondary structural rearrangements seen in the 131 cases are given in Figure 1 . As may be seen, the chromosome bands most often involved (X7 breaks) were 1q21, 1q32, 7q22, 9q34, 11q13, 11q23, 12q24, 13q14, 17q10, and 22q11.
Metaphase FISH analyses as regards 13q14 abnormalities
Chromosome band 13q14 was most often involved in structural rearrangements, being rearranged in 14 cases (Figure 1 ). Half of these were reported by Chase et al.
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who suggested a nonrandom involvement of this chromosome region in CMLs post-SCT. Only one case from our department harbored a cytogenetically visible 13q14 abnormality. In order to investigate whether such changes may be karyotypically cryptic, and hence more common than G-banding analyses would suggest, we used FISH to screen for such changes in nine cases. In three of these, the analyses were inconclusive because no BCR/ABL1-positive metaphases were observed. Among the remaining six cases, all metaphases displayed two signals of the RB1 probe. Thus, no evidence for 13q14 involvement was detected.
Discussion
The salient results of the present investigation of secondary karyotypic abnormalities in CMLs after allo-or auto-SCT are that some chromosome bands appear to be breakprone ( Figure 1 ) and that the cytogenetic evolution patterns seem to differ between post-allo-and post-auto-SCT (Table 2 ).
Prior to the present investigation, we know of four studies that have ascertained chromosome bands frequently involved in structural chromosome changes in CMLs after SCT, yielding somewhat conflicting results: 1p36, 4q34-35, 7q35, and 12q24; 21 1p22-36, 1q21-25, 9q22, 10q22, and 11q13; 22 1q32, 6p21-22, 7p21-22, and 10q21; 23 and 13q12-14. 26 Some of the presently identified breakprone regions (1q21, 1q32, 7q22, 9q34, 11q13, 11q23, 12q24, 13q14, 17q10, and 22q11) are similar to the previously reported ones, in particular the clustering of chromosome 1 breaks and the frequent involvement of 13q14 (Figure 1 ), although it should be stressed that most of the cases in the previous studies also were included in the present literature review. Considering that Chase et al. 26 reported quite a high frequency of 13q14 abnormalities but that we only had one such case, we used FISH to investigate whether 13q14 changes had been overlooked in our material. However, we found no evidence for 'cryptic' 13q14 aberrations. The reasons for the seemingly nonrandom breakpoint distribution in CMLs post-SCT (Figure 1 ) are unknown. Theoretically, two main underlying mechanisms may be involvedthese bands are particularly prone to rearrangements, they harbor genes that, if rearranged or otherwise deregulated, provide a selective advantage to the malignant clone, or a combination thereof.
To the best of our knowledge, comparisons of secondary abnormality patterns in CMLs after auto-and allo-SCT have previously not been reported. One reason for this is undoubtedly the few auto-SCT cases available; this treatment modality of CML has today become obsolete. In the present study, only nine CMLs with karyotypic evolution, or Ph-negative clones, post-auto-SCT could be Table 2 Secondary aberrations/abnormality patterns in CML after auto and allo SCT Aberrations/abnormality patterns Cytogenetic evolution in CML after SCT K Karrman et al ascertained. Although this low number makes it difficult to achieve significant and reliable P-values, some differences were noted in the present study, for example, balanced aberrations were significantly more common after allo than after auto-SCT. Furthermore, there was a trend towards significance as regards hyperdiploidy being more common after auto-SCT and pseudodiploidy being more frequent after allo-SCT ( Table 2 ). The frequencies of major route abnormalities as such did not differ between the allo-and the auto-SCT cases. However, since major route aberrations by definition should be secondary to t(9;22), cases displaying Ph-negative clones only should probably be excluded when calculating the incidence of such changes. If so, two of the three (67%) auto-SCT cases with Ph-positive clones harbored major route abnormalities, whereas the corresponding frequency for allo-SCT was 15% (16/106), a difference close to significant (P ¼ 0.07). Interestingly, a higher incidence of Ph-negative clones was found in CML cases post-auto-SCT as compared to post-allo-SCT (P ¼ 0.003; Table 2 ). However, this somewhat unexpected finding can, at least to some extent, be explained by the fact that three of the six auto-SCT cases also had been treated, post-SCT, with imatinib, which recently has been associated with the development of Ph-negative clones. [10] [11] [12] [13] [14] [15] [16] [17] Although some of the observed differences in karyotypic evolution patterns between auto-and allo-SCT CML cases may be spurious, the present data strongly indicate that balanced changes are more common after allo-SCT and that the cytogenetic features post-auto-SCT are more similar to the ones observed in non-transplanted CMLs (Table 2) . One possible reason for these differences is that BM cells used for auto-SCT usually are harvested in complete cytogenetic remission, before conditioning. A Phpositive relapse may hence originate from a leukemic cell, being present in the harvest and then transplanted back to the patient, rather than from a remaining leukemic cell in the BM. Thus, the cytogenetically abnormal clone postauto-SCT could arise from a cell not submitted to any conditioning regime -in contrast to allo-SCT where the secondary chromosomal aberrations are bound to arise in cells exposed to genotoxic agents. This explanation would support the prevailing view that the unusual secondary chromosomal changes observed post-SCT is caused by the conditioning regimen. [21] [22] [23] [24] [25] [26] However, since this treatment includes alkylators and TBI, agents strongly associated with the development of treatment-related MDS and AML with characteristic cytogenetic abnormalities, one would expect such chromosome changes also post-SCT. However, such aberrations, for example, whole or partial losses of chromosomes 5 and 7, 55 are quite rare post-SCT 20, 21, 23, 38 ( Table 3) . Thus, an alternative explanation for the atypical evolution pattern post-allo-SCT could be that the altered BM environment, that is, the presence of donor cells and/or the immunosuppression, causes or facilitates the aberrant cytogenetic evolution patterns seen post-allo-SCT. This would also agree with the present finding that aberrations post-auto-SCT seem to be similar to the ones seen in nontransplanted cases.
